https://ana.ir/en/news/11217/royan-institute-reports-preliminary-safety-findings-from-cell-therapy-trial-in-autism2026-09-17T18:28:28+03:30Royan Institute reports preliminary safety findings from cell therapy trial in autismana.pressenhttps://ana.ir/media/bb0b92cbZTp3ZWJwfGY6MTE5MTIzNS5qcGd8ZnVpOjgwOTQ5fGw6ZW58djox.webpRoyan Institute reports preliminary safety findings from cell therapy trial in autism(Tehran Ana)- Preliminary findings from a Phase I clinical trial at Royan Institute suggest that intrathecal administration of umbilical cord-derived mesenchymal stromal cells was safe and well tolerated in five children with Level 2 autism spectrum disorder.https://ana.ir/en/news/11216/whartocell-demonstrates-translational-potential-of-umbilical-cord-derived-stem-cells2026-09-17T13:27:49+03:30WhartoCell demonstrates translational potential of umbilical cord-derived stem cellsana.pressenhttps://ana.ir/media/dd5b6ddcZTp3ZWJwfGY6MTE5MTA4My5qcGd8ZnVpOjgwOTQ4fGw6ZW58djox.webpWhartoCell demonstrates translational potential of umbilical cord-derived stem cells(Tehran Ana)- Developed by Royan Institute, WhartoCell is an allogeneic, off-the-shelf cell-based therapeutic product derived from umbilical cord mesenchymal stem cells, with development spanning basic research, preclinical and clinical studies, manufacturing and regulatory processes.